Wednesday, June 16, 2010

At European League Against Rheumatism Meeting 2010

New Data From EMBLEM™ Study Show Pipeline Drug Epratuzumab Provided Significant Efficacy for Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus

Thursday, June 10, 2010

Human Genome seeks FDA nod to market lupus drug

Says files Biologics License Application with FDA

Wednesday, June 9, 2010

GSK seeks EU marketing approval for lupus drug

Says to seek U.S. FDA approval by end June

Thursday, June 3, 2010

CellCept® Has Positive Results in Phase III Lupus Nephritis Trial

Maintenance phase of Aspreva Lupus Management Study (ALMS) successfully achieves primary endpoint

Wednesday, June 2, 2010

LRI National Coalition Thanks Lady Gaga

Entertainer Speaks of Lupus to Larry King, Raises Awareness

Tuesday, April 20, 2010

News on Possible Drug for Lupus—Benlysta™

Human Genome Sciences (HGS) and GlaxoSmithKline Report Topline Results of 76-Week, Phase 3 Study

Wednesday, March 10, 2010

Ocrelizumab Trial Halted

Biogen, Roche report safety risks outweigh benefits

Thursday, February 25, 2010

Antibodies linked to cardiovascular disease increase in patients with active lupus

Study finds SLE patients at risk for developing atherosclerosis

Wednesday, February 17, 2010

CVD Risk in Lupus Worse for Men and Older Patients

Thursday, January 28, 2010

Sisters Helping Sisters: Study in Sisters of Women with SLE

Enrollment begins nationwide